- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03869892
Fase III-studie i førstelinjebehandling af patienter med metastatisk tyktarmskræft, som ikke er kandidater til intensiv terapi. (SOLSTICE)
Et åbent, randomiseret, fase III-studie, der sammenligner trifluridin/Tipiracil (S 95005) i kombination med bevacizumab med capecitabin i kombination med bevacizumab i førstelinjebehandling af patienter med metastatisk tyktarmskræft, som ikke er kandidat til intensive STØD (SOLICE-undersøgelsen)
The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Berazategui, Argentina, B1884BBF
- Centro de Oncología e Investigación de Buenos Aires COIBA
-
Buenos Aires, Argentina, C1426ANZ
- Instituto Alexander Fleming
-
Buenos Aires, Argentina, C1093AAS
- Fundación Favaloro Oncology Unit
-
Buenos Aires, Argentina, 1264
- Hospital de Gastroenterología Dr. Carlos Borino Udaondo Oncology Unit
-
Buenos Aires, Argentina, C1431FWO
- Hospital Universitario CEMIC Servicio de Oncología, Unidad de tumores gastrointestinales
-
La Rioja, Argentina, F5300COE
- Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer
-
Mendoza, Argentina, 5500
- Fundación COIR Centro Oncológico de Interación Regional
-
San Miguel de Tucumán, Argentina, T4000IAK
- Centro Médico San Roque
-
Santa Fe, Argentina, S3000FFU
- ISIS Centro especializado
-
Santa Fe, Argentina, S2000KZE
- Instituto de Oncología de Rosario
-
-
-
-
-
Blacktown, Australien, 2148
- Blacktown Hospital Cancer and Haematology Centre
-
Frankston, Australien, 3199
- Frankston Private Peninsula and Southeast Oncology Group
-
Gateshead, Australien, 2290
- Lake Macquarie Private Hospital
-
Kogarah, Australien, 2217
- St George Hospital St George Hospital Cancer Care Centre
-
Wahroonga, Australien, 2076
- Adventist HealthCare Integrated Cancer Centre
-
Wollongong, Australien, 2500
- Southern Medical Day Care Centre
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica
-
Belo Horizonte, Brasilien, 30150-320
- Cenantron - Clinica
-
Brasília, Brasilien, 70200-730
- Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa
-
Ijuí, Brasilien, 98700-000
- Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica
-
Porto Alegre, Brasilien, 90880-480
- Hospital Mae de Deus Oncologia
-
Salvador, Brasilien, 41253-191
- Hospital São Rafael Centro Intergrado de Pesquisa
-
Santo André, Brasilien, 09060-870
- CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa
-
São José do Rio Preto, Brasilien, 15090-000
- Hospital de Base Centro Integrado de Pesquisa
-
São Paulo, Brasilien, 01246-000
- ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa
-
São Paulo, Brasilien, 01509-900
- Hospital A C Camargo Unidade de Pesquisa Clinica
-
-
-
-
-
Burgas, Bulgarien, 8000
- "Complex oncology center - Burgas" EOOD Department of medical oncology
-
Gabrovo, Bulgarien, 5300
- "Multiprofile hosp. for active treatmen Dr. Tota Venkova" AD Department of medical oncology
-
Plovdiv, Bulgarien, 4004
- "Complex oncology center - Plovdiv" EOOD, IInd base Dpt. of Med. oncology and onc. diseases in gastroenterology
-
Sofia, Bulgarien, 1330
- "Medical Center Nadezhda Clinical" EOOD Medical Oncology Department
-
Sofia, Bulgarien, 1431
- "UMHAT Sv. Ivan Rilski" EAD Clinic of clinical hematology, Dpt. of medical oncology
-
Sofia, Bulgarien, 1632
- MHAT Serdika EOOD Department of Medical Oncology
-
Sofia, Bulgarien, 1756
- Spec. hospital for active treatment of oncology dis. EOOD Department of medical oncology and palliative care
-
Varna, Bulgarien, 9003
- SHAT of oncology diseases Dr. Marko Antonov Markov" EOOD Department of medical oncology and palliative therapy
-
Vratsa, Bulgarien, 3000
- "Complex Ongology Center - Vratsa" EOOD Department of Medical oncology
-
-
-
-
-
Aalborg, Danmark, 9000
- Aalborg Universitetshospital, Syd Onkologisk Afdelin
-
Copenhagen, Danmark, 2100
- Rigshospitalet Onkologisk Klinik
-
Herning, Danmark, 7400
- Regionshospitalet Herning, Hospitalsenheden Vest Onkologisk Afdeling
-
Odense, Danmark, 5000
- Odense Universitetshospital Onkologisk Afdeling R
-
-
-
-
-
Aberdeen, Det Forenede Kongerige, AB25 2ZN
- Aberdeen Royal Infirmary Oncology Department
-
Bristol, Det Forenede Kongerige, BS2 8ED
- University Hospitals Bristol Bristol Haematology & Oncology Centre
-
Leeds, Det Forenede Kongerige, LS9 7TF
- St James's University Hospital
-
Leicester, Det Forenede Kongerige, LE1 5WW
- Leicester Royal Infirmary The HOPE Clinical Trials Unit
-
London, Det Forenede Kongerige, SW3 6JJ
- Royal Marsden Hospital Department of Medicine
-
London, Det Forenede Kongerige, W12 0HS
- Hammersmith Hospital Gary Weston Centre
-
London, Det Forenede Kongerige, W1G 6AD
- Sarah Cannon Research Institute UK Clinical Trials
-
London, Det Forenede Kongerige, W6 8RF
- Imperial Healthcare NHS Trust Charing Cross Hospital
-
Manchester, Det Forenede Kongerige, M20 4BX
- Christie Hospital NHS Foundation Trust GI & Endocrine
-
Rhyl, Det Forenede Kongerige, LL18 5UJ
- Glan Clwyd Hospital North Wales Cancer Treatment Centre
-
Sutton, Det Forenede Kongerige, SM2 5PT
- Royal Marsden Hospital Department of Medicine
-
-
-
-
-
Tallinn, Estland, 11312
- East Tallinn Central Hospital Center of Oncology
-
Tallinn, Estland, 13419
- North Estonia Medical Centre Foundation Oncology and Haematology clinic
-
Tartu, Estland, 51014
- Tartu University Hospital, Hematology - Oncology clinic, Radiotherapy and oncological therapy
-
-
-
-
-
Avignon, Frankrig, 84918
- Institut Sainte Catherine
-
Besançon, Frankrig, 25030
- CHU Jean Minjoz Service d'oncologie médicale
-
Brest, Frankrig, 29200
- CHU Morvan Institut de Cancérologie et d'Hématologie
-
Lyon, Frankrig, 69008
- Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale
-
Montbéliard, Frankrig, 25209
- Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale
-
Nice, Frankrig, 06189
- Centre Antoine Lacassagne Dpt d'Oncologie Médicale
-
Paris, Frankrig, 75012
- Hôpital Saint-Antoine Service d'Oncologie Médicale
-
Paris, Frankrig, 75015
- Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive
-
Pessac, Frankrig, 33604
- Hopital Haut-Leveque Hepato-gastroenterologie et oncologie digestive
-
Toulouse, Frankrig, 31059
- CHU Toulouse Rangueil Oncologie médicale digestive
-
-
-
-
-
Arnhem, Holland, 6815 AD
- Rijnstate Oncologie
-
Dordrecht, Holland, 3318 AT
- Albert Schweitzer Ziekenhuis Interne Geneeskunde
-
Eindhoven, Holland, 5623 EJ
- Catharina Ziekenhuis Interne Gesneeskunde/Oncologie
-
Rotterdam, Holland, 3083 AN
- Ikazia Ziekenhuis Oncologie
-
Tilburg, Holland, 5022 GC
- ETZ Elisabeth Interne Geneeskunde
-
Uden, Holland, 5406 PT
- Bernhoven Interne Geneeskunde
-
-
-
-
-
Cork, Irland, 90
- Bon Secours Hospital
-
Cork, Irland, T12 DC4A
- Cork University Hospital Department of Medical Oncology
-
Dublin, Irland, D24 NROA
- The Adelaide and Meath Hospital
-
-
-
-
-
Cagliari, Italien, 09100
- Azienda Policlinico Universitaria - Presidio Monserrato Oncologia Medica
-
Cremona, Italien, 26100
- Azienda Socio Sanitaria Territoriale di Cremona ONCOLOGIA
-
Naples, Italien, 80131
- Istituto Nazionale Tumori I.R.C.C.S "Fondazione G. Pascale" Struttura Complessa di Oncologia Medica Addominale
-
Padova, Italien, 35128
- Istituto Oncologico Veneto IOV - IRCCS Unità Operativa Complessa Oncologia Medica 1
-
Pisa, Italien, 56126
- A.O.U. Pisana-Ospedale Santa Chiara U.O. di Oncologia Medica 2
-
Potenza, Italien, 85100
- Ospedale San Carlo U.O. Oncologia Medica
-
Reggio Emilia, Italien, 42123
- Arcispedale Santa Maria Nuova Unità di Oncologia
-
Roma, Italien, 00128
- Policlinico Universitario Campus Biomedico UOC di Oncologia Medica
-
Rozzano (MI), Italien, 20089
- Istituto Clinico Humanitas I.R.C.C.S Dipartimento di Oncologia Medica ed Ematologia
-
San Giovanni Rotondo, Italien, 71013
- IRCSS Casa Sollievo della Sofferenza Dipartimento Onco-Ematologia
-
Vicenza, Italien, 36100
- Ospedale S. Bortolo -ULSS8 Berica Distretto Est U.O. ONCOLOGIA
-
-
-
-
-
Riga, Letland, 1079
- Riga East Univerity Hospital Oncology Centre of Latvia
-
Riga, Letland, 1002
- P. Stradins Clinical University Hospital
-
-
-
-
-
Kaunas, Litauen, 45434
- Oncology Hospital, Branch of Hospital of Lithuanian Uni. of Health Sciences Kauno klinikos
-
Kaunas, Litauen, LT-50161
- Hospital of Lithuania Univ of Health Sciences Kauno klinikos Oncology Institute
-
Klaipėda, Litauen, 92288
- Klaipeda University hospital
-
Vilnius, Litauen, LT-08660
- National Cancer Institute
-
-
-
-
-
Bialystok, Polen, 15-027
- Bialostockie Centrum Onkologii im Marii Curie-Sklodowskiej Oddzial Onkologii Klinicznej im Dr Ewy Pileckiej z pododdzialem Chemioterapii Dziennej
-
Gdansk, Polen, 80-952
- Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii
-
Konin, Polen, 62-500
- Przychodnia Lekarska "KOMED"
-
Lodz, Polen, 93-513
- M. Kopernika Provincial Hospital Oddzial Chemioterapii Nowotworow
-
Olsztyn, Polen, 10-228
- SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii Oddzial Kliniczny Onkologii i Immunoonkologii
-
Opole, Polen, 45-061
- Opolskie Centrum Onkologii im. Tadeusza Koszarowskiego Oddzial Onkologii Klinicznej
-
Poznan, Polen, 61-866
- Wielkopolskie Centrum Onkologii im Marii Sklodowskiej-Curie Oddzial Chemioterapii
-
Tomaszów Mazowiecki, Polen, 97-200
- NU-MED Centrum Diagnostyki i Terapii Onkologicznej Tomaszów Mazowiecki II Sp. z o.o., Pododdzial Chemioterapi
-
-
-
-
-
Almada, Portugal, 2805-267
- Hospital Garcia de Orta Serviço de Oncologia Médica
-
Coimbra, Portugal, 3000-075
- Centro Hospitalar e Universitário de Coimbra - CHUC Unidade de Inovação e Desenvolvimento (UID)
-
Lisbon, Portugal, 1649-035
- Centro Hospitalar Lisboa Norte, Hospital de Santa Maria Serviço de Oncologia Médica
-
Loures, Portugal, 2674-514
- Hospital Beatriz Ângelo Serviço de oncologia medic
-
Porto, Portugal, 4200-072
- Instituto Português de Oncologia do Porto FG, EPE -IPO Porto Medical Oncology Dept.
-
-
-
-
-
Bucharest, Rumænien, 022328
- Institutul Oncologic "Prof Alexandru Trestioreanu" Busuresti Sectia Oncologie Medicala I
-
Bucharest, Rumænien, 030171
- Spitalul Clinic "Coltea" Sectia Oncologie Medicala
-
Cluj-Napoca, Rumænien, 400015
- Institutul Oncologic "Prof. Dr. I. Chiricuta" Cluj Napoca Oncologie Medicala
-
Craiova, Rumænien, 200347
- Centrul de Oncologie Sf Nectarie Oncology Department
-
Craiova, Rumænien, 200385
- S.C Oncolab S.R.L Sectia Oncologie Medicala
-
Iași, Rumænien, 700483
- Institutul Regional de Oncologie Iasi Clinica de Oncologie Medicala
-
Sibiu, Rumænien, 550245
- Spitalul Clinic Judetean de Urgenta Sibiu Sectia Oncologie Medicala
-
Timișoara, Rumænien, 300239
- S.C ONCOMED S.R.L Departament Oncologie Medicala
-
-
-
-
-
Arkhangelsk, Rusland, 163045
- Arkhangelsk Clinical Oncology Dispensary chemotherapy department
-
Krasnodar, Rusland, 350040
- Clinical Oncology Dispensary No.1 Chemotherapy Department
-
Kursk, Rusland, 305524
- Kursk Regional Clinical Oncology Dispensary Oncology Department
-
Moscow, Rusland, 115478
- Russian Cancer Research Center n.a. NN Blokhin Clinical Pharmacology and Chemotherapy
-
Moscow, Rusland, 121467
- University Headache Clinic Outpatient oncology clinic
-
Moscow, Rusland, 143423
- Moscow City Oncology Hospital # 62 chemotherapy department
-
Omsk, Rusland, 644046
- Omsk Clinical Oncologic Dispensary Chemotherapy
-
Pyatigorsk, Rusland, 357502
- Pyatigorsk Interdistrict Oncology Dispensary Chemotherapy department
-
Rostov-on-Don, Rusland, 344037
- Rostov Research Institute of Oncology Chemotherapy department
-
Ryazan, Rusland, 390011
- Regional Clinical Oncology Dispensary
-
Saint Petersburg, Rusland, 115478
- Scientific Centre for Specialized Medical Care (oncological) Chemotherapy
-
Saint Petersburg, Rusland, 197758
- National Medical Research Center of Oncology N.N. Petrova
-
Saint Petersburg, Rusland, 198255
- Saint Petersburg City Oncology Clilnic
-
Samara, Rusland, 443011
- Multidisciplinary clinic "Reaviz"
-
Sochi, Rusland, 354057
- Oncology Dispensary No.2
-
Tomsk, Rusland, 634024
- State Research Institution of Oncology of Tomsk Chemotherapy
-
Yaroslavl, Rusland, 150054
- SBIH of YR "Clinical oncology hospital" chemotherapy department
-
-
-
-
-
Bratislava, Slovakiet, 833 10
- Narodny onkologicky ustav Oddelenie klinickej onkologie
-
Košice, Slovakiet, 04191
- Vychodoslovensky onkologicky ustav Oddelenie klinickej onkologie
-
-
-
-
-
Alicante, Spanien, 03010
- Hospital General Universitario Alicante Servicio de Oncología
-
Badalona, Spanien, 08916
- Hospital Germans Trias i Pujol Unidad de Investigación clínica (UIC) ICO-Oncología medica
-
Barcelona, Spanien, 08035
- H. Valle de Hebrón Servicio de Oncología - (VHIR)
-
Barcelona, Spanien, 08041
- Hospital de la Santa Creu I Sant Pau Oncología Medica
-
Córdoba, Spanien, 14004
- Hospital Uni. Reina Sofía - Hospital Provincial Departamento de Oncología Médica
-
L'Hospitalet de Llobregat, Spanien, 08908
- INSTITUTO CATALAN DE ONCOLOGÍA - ICO Oncología Médica
-
Madrid, Spanien, 28034
- Hospital Universitario Ramón y Cajal, Servicio de Oncologia Médica
-
Madrid, Spanien, 28007
- Hospital Unviersitario Gregorio Marañon Servicio de Oncología Médica
-
Madrid, Spanien, 28040
- H. Clínico San Carlos Servicio de Oncología Médica
-
Madrid, Spanien, 28041
- HOSPITAL 12 DE OCTUBRE Servicio Oncología Médica
-
Madrid, Spanien, 28046
- H. Universitario La Paz Oncología Médica
-
Santander, Spanien, 39008
- Hospital Universitario Marqués de Valdecilla Oncología médica
-
Seville, Spanien, 41013
- H.Virgen Del Rocio
-
Valencia, Spanien, 46010
- Hospital Quirónsalud Valencia Servicio de Oncología Médica
-
Zaragoza, Spanien, 50009
- Hospital Universitario Miguel Servet Servicio de Oncología
-
-
-
-
-
Falun, Sverige, 791 82
- Falu Lasarett Onkologmottagningen
-
Jönköping, Sverige, 551 85
- Lanssjukhuset Ryhov Onkologiska kliniken
-
Solna, Sverige, 171 64
- Karolinska University Hospital, Solna Studiebehandlingsenheten, B8:09
-
Umeå, Sverige, 901 85
- Norrlands Universitetssjukhus Cancercentrum Umea
-
Örebro, Sverige, 701 85
- Universitetssjukhuset Orebro
-
-
-
-
-
Brno, Tjekkiet, 656 53
- Masarykuv onkologicky ustav Klinika komplexni onkologicke pece
-
Ostrava, Tjekkiet
- Fakultni nemocnice Ostrava Klinika onkologicka
-
Prague, Tjekkiet, 128 08
- Vseobecna fakultni nemocnice Onkologicka klinika VFN a 1. LF UK
-
Prague, Tjekkiet, 140 59
- Thomayerova nemocnice Onkologicka klinika 1. LF UK a TN
-
Prague, Tjekkiet, 77900
- Fakultni nemocnice Olomouc Onkologicka klinika
-
-
-
-
-
Berlin, Tyskland, 10707
- Onkologische Schwerpunktpraxis Kurfuerstendamm
-
Lübeck, Tyskland, 23562
- Lübecker Onkologische Schwerpunktpraxis im Hochschulstadttei
-
München, Tyskland, 81377
- Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III
-
-
-
-
-
Cherkasy, Ukraine, 18009
- Cherkasy Regional Oncological Dispensary Regional Clinical Oncological Centre
-
Dnipro, Ukraine, 49055
- Dnipro Regional Oncology Dispensary
-
Dnipro, Ukraine, 49102
- MI "Dnipropetrovsk City Multi-field Clinical Hospital #4" Department of Oncology
-
Kharkiv, Ukraine, 61024
- Institute of Medical Radiology of S.P. Grygoryev of AMS UKR
-
Kyiv, Ukraine, 03022
- National Institute of Cancer Abdominal Oncology Department
-
Kyiv, Ukraine, 03115
- Kyiv City Clinical Oncology Centre Chemotherapy Department #2
-
Kyiv, Ukraine, 04107
- Municipal Institution of Kyiv Regional Council "Kyiv Regional Clinical Hospital", proctology department
-
Lviv, Ukraine, 79031
- Lviv Regional Oncology Center Chemotherapy department
-
Odesa, Ukraine, 65010
- Odesa Regional Oncology Dispensary Day patient Department
-
Vinnytsia, Ukraine, 21029
- Podillia Regional Oncology Centre Chemotherapy Department
-
Zaporizhzhya, Ukraine, 69000
- Regional Clinical Oncological Dispensary Department of Oncology
-
-
-
-
-
Budapest, Ungarn, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly
-
Budapest, Ungarn, 1083
- Semmelweis University Radiology and Oncotherapy Clinic
-
Budapest, Ungarn, 1097
- Del-Pesti Centrumkh-Orsz. Hematologiai es Infektologiai Int. Szent Laszlo Telephely
-
Budapest, Ungarn, 1115
- Szent Imre Egyetem Oktatokorhaz Klinikai Onkologia
-
Budapest, Ungarn, 1122
- Orszagos Onkologiai Intezet "B" Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O.
-
Budapest, Ungarn, 1145
- Uzsoki Utcai Korhaz Onkoradiologiai Osztaly
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet
-
Gyula, Ungarn, 57000
- Bekes Megyei Kozponti Korhaz
-
Győr, Ungarn, 9024
- Petz Aladar Megyei Oktato Korhaz Onkoradiologiai Osztaly
-
Kecskemét, Ungarn, 6000
- Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont
-
Nyíregyháza, Ungarn, 4400
- Szabolcs-Szatmar-Bereg Megyei Korhazak Onkoradiologiai Osztaly
-
Pécs, Ungarn, 7624
- Pecsi Tudomanyegyetem, Klinikai Kozpont Onkoterapias Intezet
-
Szeged, Ungarn, 6720
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kp. Onkoterápiás Klinika
-
Szolnok, Ungarn, 5004
- JNSZ Megyei Hetenyi Geza Korhaz es Rendelointezet Megyei Onkologiai Centrum
-
Szombathely, Ungarn, 9700
- Markusovsky Egyetemi Oktatokorhaz Onkoradiologiai Osztaly
-
Zalaegerszeg, Ungarn, 8900
- Zala Megyei Korhaz Onkologiai osztaly
-
-
-
-
-
Graz, Østrig, 8036
- Med. Universität Graz Klinische Abteilung für Onkologie
-
Innsbruck, Østrig, 6020
- Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V
-
Linz, Østrig, 4010
- Ordensklinikum Linz Barmherzige Schwestern Interne I
-
Salzburg, Østrig, 5020
- Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)
-
Sankt Pölten, Østrig, 3100
- Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I
-
Vienna, Østrig, 1090
- Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded). Primary tumour localisation must be known.
-
RAS status based on local biological assessment of tumour biopsy must be available. If RAS status is not available at the time of randomisation, tumour biopsy must be available for RAS status determination (based on local biological assessment).
-
Patient is not a candidate for standard full dose combination chemotherapy with irinotecan or oxaliplatin
-
Patient is not a candidate for curative resection of metastatic lesions.
-
No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.
-
ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
-
Adequate organ function (renal, haematological, hepatic, coagulation) as described in the study protocol'
Exclusion Criteria:
-
Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
-
Participation in another interventional study within 4 weeks prior to the randomisation .
-
Patients who have not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to the randomisation.
-
Symptomatic central nervous system metastases.
-
Major surgery within 4 weeks prior to the randomisation.
Exclusion criteria related to S 95005 administration:
-
History of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipients.
-
Any contraindication present in the SmPC of trifluridine/tipiracil
Exclusion criteria related to bevacizumab administration:
-
Any contraindication present in the SmPC of bevacizumab
Exclusion criteria related to capecitabine administration:
-
Any contraindication present in the SmPC of capecitabine
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: S95005 + Bevacizumab
|
Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks. Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks. |
|
Aktiv komparator: Capecitabin + Bevacizumab
|
Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks. Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: Up to 24 months
|
Time elapsed between the randomization and the date of radiological tumour progression (according to RECIST 1.1) or death from any cause. |
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomsten af bivirkninger (AEs)
Tidsramme: Op til 8 år
|
Op til 8 år
|
|
|
Antal klinisk signifikante ændringer i hæmatologi-, biokemi-, koagulations- og urinanalyseprøver
Tidsramme: Op til 8 år
|
Op til 8 år
|
|
|
Ændringer i ECOG præstationsstatus
Tidsramme: Op til 8 år
|
Op til 8 år
|
|
|
Antal klinisk signifikante ændringer i blodtryk, hjertefrekvens, kropstemperatur og kropsvægt
Tidsramme: Op til 8 år
|
Op til 8 år
|
|
|
Antal klinisk signifikante ændringer i 12-leds EKG-parametre
Tidsramme: Op til 8 år
|
Op til 8 år
|
|
|
Overall Survival (OS)
Tidsramme: Up to 8 years
|
Time elapsed between the date of randomization and the date of death due to any cause. |
Up to 8 years
|
|
Overall response rate (ORR)
Tidsramme: Up to 8 years
|
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and using investigator's tumour assessment. |
Up to 8 years
|
|
Disease control rate (DCR)
Tidsramme: Up to 8 years
|
The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1 criteria and using investigator's tumour assessment. |
Up to 8 years
|
|
Duration of response (DoR)
Tidsramme: Up to 8 years
|
The time from the first documentation of response (CR or PR) to the first documentation of objective tumour progression or death due to any cause, whichever occurs first. |
Up to 8 years
|
|
Time to treatment failure (TTF)
Tidsramme: Up to 8 years
|
The time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death. |
Up to 8 years
|
|
Quality of life as assessed by EORTC QLQ-C30
Tidsramme: Up to 8 years
|
European organization for research and treatment of cancer (EORTC) Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) scores range from 0-100 and assess functional and symptom scores. For functional scores, a higher score represents an increase in functioning. For symptom scores, a higher score represents an increase in symptoms. |
Up to 8 years
|
|
Quality of life as assessed by EQ-5D-5L
Tidsramme: Up to 8 years
|
The 5-level EQ-5D version questionnaire scores range from 5 to 25 with a higher score representing a worse health status. |
Up to 8 years
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Thierry ANDRE, PhD, Medical Oncology departement Saint-Antoine hospital (Paris France 75012)
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer efter sted
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Neoplastiske processer
- Patologiske tilstande, tegn og symptomer
- Neoplasmer
- Kolorektale neoplasmer
- Neoplasma Metastase
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Nukleosider
- Uracil
- Pyrimidinoner
- Deoxyribonucleosider
- Fluorouracil
- Thymidin
- Capecitabin
- Trifluridin
Andre undersøgelses-id-numre
- CL3-95005-006
- 2017 (U.S. NIH-bevilling/kontrakt)
- 2017-004059-22 (EudraCT nummer)
- U1111-1206-3198 (Anden identifikator: UTN)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD-delingstidsramme
After Marketing Authorisation in EEA or US if the study is used for the approval.
IPD-delingsadgangskriterier
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Studiedata/dokumenter
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .